Precigen's Q3 2026 Financials Show Strong Growth and Positive Cash Flow for PAPZIMEOS Therapy

Precigen Reports Robust Q3 2026 Results

In a significant announcement on November 4, 2026, Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company focused on innovative precision medicines, revealed its financial results for the third quarter of 2026. The company reported a remarkable 37% quarter-over-quarter increase in revenue from its product PAPZIMEOS®, reaching $72.9 million. This surge brings the total net product revenue since launch to approximately $151 million.

The achieving of positive cash flow in the third quarter was a full quarter ahead of the company's guidance, showcasing Precigen's operational strength and market acceptance. With net income reported at $35.8 million, the financial position of the company appears strong as it continues to capitalize on the momentum gained in the market.

Helen Sabzevari, PhD, the President and CEO of Precigen, emphasized the company’s strong positioning in the biopharmaceutical landscape. She stated, “PAPZIMEOS has transformed treatment for adults with recurrent respiratory papillomatosis (RRP), with more than 500 patients starting treatment, and upwards of 300 completing it. The therapy has emerged as the first-line standard of care due to its compelling efficacy and safety profile.”

PAPZIMEOS - Redefining Treatment Approaches

PAPZIMEOS (zopapogene imadenovec-drba) represents a groundbreaking advancement in the management of RRP, a condition historically treated through multiple surgeries. The therapy employs a non-replicating adenoviral vector to trigger an immune response against HPV 6 and 11, which are the main causes of RRP. Its remarkable 51% complete response rate post-treatment—indicating patients required no further surgeries for twelve months—has established new benchmarks for efficacy in the field.

Clinical data presented at the recent 2026 American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting highlighted sustained treatment responses lasting up to five years, further supporting the therapy's long-term viability.

The therapeutic's administrative protocol is also streamlined; it is delivered subcutaneously, eliminating the need for specialized devices—a factor that has facilitated its adoption across various clinical environments. Notably, PAPZIMEOS has received full FDA approval without requiring additional confirmatory trials, underscoring its credibility and effectiveness.

Platform Technology Advancement

In a parallel advancement, Precigen announced the receipt of FDA Platform Technology Designation for its AdenoVerse® platform. This milestone will enable faster development of existing and future therapies by allowing the application of pre-existing manufacturing and preclinical data across different candidates, ultimately enhancing efficiency in the development pipeline.

As a testament to its commercial adoption, PAPZIMEOS has been included in comprehensive payer networks, providing access to over 315 million insured lives across the United States. The establishment of a permanent J-code for reimbursement aids in the financial aspects of the treatment for both healthcare providers and patients.

Looking Ahead: Strategic Growth Initiatives

The firm is strategically advancing several initiatives aimed at expanding the PAPZIMEOS portfolio. This includes ongoing studies for redosing, pediatric development, and geographic expansion. Additionally, Precigen is actively pursuing an application for marketing authorization within the European Medicines Agency for PAPZIMEOS.

With a significant first-mover advantage, strong revenue growth, and a commitment to operational excellence, Precigen is well-positioned for sustained success in the biotechnology sector. The company's strong financial results are a clear reflection of its impactful innovations and the growing recognition of PAPZIMEOS within the medical community.

In summary, Precigen continues to thrive, paving the way for innovative treatments and demonstrating its firm commitment to improving the lives of patients through precision medicine.